BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LN-145-S1 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LN-145-S1\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03449108-7651@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:LN-145-S1: Phase 2 readout est. (NCT03449108)
DESCRIPTION:LN-145-S1\, phase 2.\nStudy: LN-145 or LN-145-S1 in Treating Pa
 tients With Relapsed or Refractory Ovarian Cancer\, Triple Negative Breast
  Cancer (TNBC)\, Anaplastic Thyroid Cancer\, Osteosarcoma\, or Other Bone 
 and Soft Tissue Sarcomas\nEstimated primary completion: 30 April 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ln-145-s1#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03449108
URL:https://assetmemo.bio/drug/ln-145-s1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
